Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in Advanced, Metastatic, or Recurrent Endometrial and Ovarian Cancers
NCT01550380Phase 2Withdrawn
- Sponsor
- University of Utah
- Start
- May 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buparlisib in endometrial cancer (EC), ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by University of Utah. Planned start May 2014; status: withdrawn.
02
Drugs
buparlisib
03
Conditions
endometrial cancer (EC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01550380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01550380.